Liana Moussatos

Latest articles

1m
Market Watch
Ascendis Pharma shares surge 42% as competitor Versartis plummets 85% on failed trialand the Versartis product had been expected to launch about a year earlier than
Market Watch / Posted a month ago
and the Versartis product had been expected to launch about a year earlier than Ascendis Pharma’s. Wedbush analyst Liana Moussatos raised Ascendis Pharma’s price target nearly 81% to $65 on Friday, calling Versartis’ human growth hormone... Read more

In this news